Version 1
: Received: 27 March 2024 / Approved: 28 March 2024 / Online: 28 March 2024 (05:57:01 CET)
How to cite:
Och, A.; Lemieszek, M.K.; Cieśla, M.; Jedrejek, D.; Kozłowska, A.; Pawelec, S.; Nowak, R. Berberis vulgaris L. Root Extract as a Multi-target Chemopreventive Agent against Colon Cancer. Preprints2024, 2024031731. https://doi.org/10.20944/preprints202403.1731.v1
Och, A.; Lemieszek, M.K.; Cieśla, M.; Jedrejek, D.; Kozłowska, A.; Pawelec, S.; Nowak, R. Berberis vulgaris L. Root Extract as a Multi-target Chemopreventive Agent against Colon Cancer. Preprints 2024, 2024031731. https://doi.org/10.20944/preprints202403.1731.v1
Och, A.; Lemieszek, M.K.; Cieśla, M.; Jedrejek, D.; Kozłowska, A.; Pawelec, S.; Nowak, R. Berberis vulgaris L. Root Extract as a Multi-target Chemopreventive Agent against Colon Cancer. Preprints2024, 2024031731. https://doi.org/10.20944/preprints202403.1731.v1
APA Style
Och, A., Lemieszek, M.K., Cieśla, M., Jedrejek, D., Kozłowska, A., Pawelec, S., & Nowak, R. (2024). <em>Berberis vulgaris</em> L. Root Extract as a Multi-target Chemopreventive Agent against Colon Cancer. Preprints. https://doi.org/10.20944/preprints202403.1731.v1
Chicago/Turabian Style
Och, A., Sylwia Pawelec and Renata Nowak. 2024 "<em>Berberis vulgaris</em> L. Root Extract as a Multi-target Chemopreventive Agent against Colon Cancer" Preprints. https://doi.org/10.20944/preprints202403.1731.v1
Abstract
Berberis vulgaris L. (Berberidaceae) is a shrub that has been widely used in European folk medicine as an anti-inflammatory and antimicrobial agent. The purpose of our study was to elucidate the mechanisms of antiproliferative action of the plant’s methanolic root extract (BVR) against colon cancer cells. Cytotoxicity and pro-apoptotic activity were determined in human colon adenocarcinoma cell lines (LS180 and HT-29) and control colon epithelial CCD841 CoN cells. According to the MTT assay, after 48 h of cell exposure, the IC50 values were as follows: 4.3; 46.1 and 50.2 µg/mL for LS180, HT-29, and CCD841 CoN cells, respectively, showing the greater sensitivity of cancer cells to BVR. The Cell Death Detection ELISAPLUS kit demonstrated that BVR induced programmed cell death only against HT-29 cells. RT-qPCR with relative quantification method showed significant changes in the expression of genes related to apoptosis in both colon cancer cell lines. The genes BCL2L1 (126.84-366.66%), BCL2L2 (277.08-330.12%), CASP3 (180.36-261.36%) and CASP9 (158.08-213.46%) had significantly elevated expression, while BCL2 (23.08-52.06%) had reduced expression. Furthermore, in a panel of antioxidant tests, BVR showed positive effects (63.93±0.01, 122.92±0.01, and 220.29±0.02 mg Trolox equivalents (TE)/g in the DPPH•, ABTS•+ and ORAC assays, respectively). In the lipoxygenase (LOX) inhibition test, BVR revealed 62,60±0.87% of enzyme inhibition. The chemical composition of BVR was determined using UHPLC-UV-CAD-MS/MS analysis and confirmed the presence of several known alkaloids, including berberine, as well as other alkaloids and two derivatives of hydroxycinnamic acid (ferulic and sinapic acid hexosides). This is the first such extensive assessment of the biological activity of BVR. The results are very promising and encourage for the use of BVR as a comprehensive chemopreventive agent (anti-inflammatory, antioxidant, and pro-apoptotic) in colorectal cancer.
Medicine and Pharmacology, Complementary and Alternative Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
